Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$60.30
HK$0.45(1.61%)
At close: 4:00 PM EST
HK$60.30
HK$0.45(1.61%)
Day’s Range― - ―
52-Week RangeHK$31.84 - HK$71.70
Previous CloseN/A
Volume5.25M
Average Volume (3M)7.60M
Market Cap
HK$115.92B
Enterprise ValueHK$66.87B
Total Cash (Recent Filing)HK$48.15B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)17.6
Beta1.42
Next Earnings
Aug 13, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,211,075,200
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$68.05Price Target Upside12.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.8
Revenue Forecast (FY)HK$86.49B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage Balance SheetExtremely low leverage provides durable financial flexibility: the company can fund growth, R&D and cautious offline expansion from internal resources, absorb cyclical shocks, and avoid refinancing stress. This balance-sheet strength underpins multi-year investments in AI and supply chain.
Sustained Revenue And Profit GrowthConsistent double-digit top-line growth and materially faster non‑IFRS profit expansion show improving unit economics and scale. Over several quarters the company delivered >20% revenue growth and margin gains, supporting continued reinvestment and long-term profitability improvements.
Scale In Pharmaceutical Supply Chain And JD SupportA scaled, integrated supply chain with parent-company logistics creates structural cost and service advantages. It supports higher gross margins, faster fulfillment for on‑demand retail and product launches, and provides barriers to smaller rivals across retail, pharmacy and insurance channels.
Bears Say
Free Cash Flow Drop In 2025A one-year reset to zero free cash flow signals higher capex or working-capital strain that weakens near-term financial flexibility. Even with healthy operating cash flow and cash balances, inconsistent FCF raises risk around funding AI commercialization, offline rollout, and sustaining buybacks or payouts.
Revenue Concentrated In Direct SalesHeavy reliance on direct-sales exposes earnings to supplier, pricing and category cycles and reduces diversification. A concentrated revenue mix makes margins and growth more sensitive to product mix shifts or supplier disruptions, increasing the need to scale service and insurance channels for resilience.
AI Commercialization Remains UncertainHigh user engagement with AI tools is encouraging, but an unclear monetization path creates execution risk. Large AI investments without proven B2B/B2C revenue streams could press margins and capital needs if conversion to paid products or partner deals lags expectations.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$31.84 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$115.92B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 38 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.08 earnings per share for the quarter, beating the consensus estimate of HK$0.751 by HK$0.329.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.35.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,211,075,200 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.08 in its last earnings report, beating expectations of HK$0.751. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
9.11%
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$68.05
▲(12.86% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---